Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Crit Rev Oncol Hematol. 2008 Jul;67(1):1-7. doi: 10.1016/j.critrevonc.2008.01.007. Epub 2008 Mar 14.

Targeting AMPK: a new therapeutic opportunity in breast cancer.

Author information

  • 1Department of Surgery and Molecular Oncology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom. s.hadad@dundee.ac.uk

Abstract

BACKGROUND:

This paper reviews the mammalian Target Of Rapamycin (mTOR) pathway dysregulation in breast cancer, and the current evidence targeting this pathway directly or through activation of AMP-activated protein kinase (AMPK) as an additional therapeutic opportunity for intervention in breast cancer.

METHODS:

Relevant articles were identified through computerised searches of Medline and Pubmed. Secondary articles were identified from the reference lists of key papers and by hand searching.

RESULTS AND CONCLUSION:

The current consensus to target the AMPK/mTOR pathway in breast cancer is based on in vitro and epidemiological evidences. A low incidence of cancer in diabetic patients on metformin has been explained in vitro by the drug's anti-proliferative effect through activation of AMPK. There is a need to explore the anticancer effects of metformin and the potential to develop the therapeutic avenues offered by targeting the AMPK/mTOR pathway.

PMID:
18343152
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk